Improve patient outcomes for colorectal cancer screening with Labcorp’s FIT test

As you may be aware, the U.S. Preventive Services Task Force (USPSTF) issued updated guidelines recommending screening for colorectal cancer to begin at age 45.¹ The USPSTF considers highly sensitive fecal occult blood tests (FOBT) as a good option for colorectal cancer screening. The FDA has approved fecal immunohistochemical testing (FIT also known as iFOBT) for ectal cancer screening in average risk patients. When FIT is performed at the recommended intervals, it has similar specificity and sensitivity to stool-based DNA tests.

 

Labcorp* is our preferred lab provider and has a cost-effective colorectal cancer screening option that provides high sensitivity and specificity while enabling patient ease, convenience, and satisfaction. You can improve patient compliance for colorectal cancer screening with Labcorp’s fecal immunohistochemical testing (FIT) kit. Labcorp’s FIT kit provides your patients with everything they need to complete the sample collection at home and mail it back to Labcorp. In addition, the kit is easy to use, requiring no special preparation or direct stool contact.

 

When you use Labcorp you’ll have:

• Electronic delivery of results to your electronic medical records (EMR) system, making documentation of screening results easier for you and your office staff.
• Patient friendly in-home collections.
• 99.1% sensitivity and 100% specificity,² resulting in a high-quality test.

 

For more information

To obtain FIT kits for your office or for more information, contact your local Labcorp sales representative.  You can also visit www.labcorp.com/cancer/colorectal/providers for additional ordering details.

 

References

1 https://www.cdc.gov/cancer/ectal/basic_info/screening/index.htm#:~:text=Regular%20screening%2C%20beginning%20at%20age,to%20their%20doctor%20about%20screening.

2 https://journals.sagepub.com/doi/10.1177/2150131917705206

 

* Labcorp is an independent company providing laboratory services on behalf of Anthem Blue Cross and Blue Shield.

 

NVBCBS-CM-009046-22